A carbon-based biosensing platform simultaneously measured contraction and electrophysiology of iPSC-cardiomyocyte monolayers, validating its use for disease modeling and drug testing.
A novel carbon-based biosensing platform enables simultaneous measurement of contraction and electrophysiology in iPSC-cardiomyocyte monolayers for disease modeling and drug testing.
model of drug-induced cardiac arrhythmia was established to further validate the platform for disease modeling and drug testing.
Dou et al. (2022) studied this question. A carbon-based biosensing platform simultaneously measured contraction and electrophysiology of iPSC-cardiomyocyte monolayers, validating its use for disease modeling and drug testing.